warnings
WARNINGS Accidental Exposure in Children: the potential exists for a small child or a pet to suffer adverse effects from chewing or ingesting a new or used DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage. It is important for patients to store and dispose of DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage out of the reach of children and pets. For external use only. The DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage may interfere with the operation of a cardiac pacemaker or defibrillator. Consultation with the attending cardiologist is recommended. The DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage should be removed prior to any imaging procedures (e.g. CT scan, MRI, etc.). The DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage should not be used if there are mental or physical conditions that may preclude compliance with physician instructions. Do not use on infected skin, deep puncture wounds, animal bites, serious burns or blistered areas. PRECAUTIONS: When traveling by air, do not wear the DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIP bandage when passing through passenger screening devices or the BIOFREQUENCY CHIP could be damaged. Application to broken or inflamed skin, although not tested, may result in higher blood concentrations from increased absorption. DIMETHICONE, ALLANTOIN BIOfrequency Chip bandage is only recommended for use on intact skin. The contact of DIMETHICONE, ALLANTOIN BIOFREQUENCY CHIPs with eyes, although not studied, should be avoided based on the findings of severe eye irritations with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Nonclinical toxicity studies to determine the potential of this topical preparation to cause carcinogenicity or mutagenicity have not been performed. The effect of the product on fertility has not been evaluated in animals. ADVERSE REACTIONS: The most common adverse reactions are application site reactions, including dermatitis, irritation, itching or scaling. These tend to be dose-limiting and diminish with time. If severe erythema, edema, vesicle formation (e.g., vesicular rash), or crusting develops, Colliginix should be discontinued until skin integrity is restored. Therapy may be reinitiated with less frequent application.